SCDF StaffFeb 212 minFDA Approves Novartis' Adakveo for Pain Events Associated with Sickle Cell DiseaseThe U.S.Food and Drug Administration (FDA)approvedNovartis’ Adakveo (crizanlizumab) to decrease the frequency of vaso-occlusive crises...
SCDF StaffFeb 213 minFDA Approves Oxbryta™, First Medicine Specifically Targeting the Root Cause of Sickle Cell DiseaseOxbryta (voxelotor), a first sickle cell treatment that works to stop the sickling and destruction of red blood cells that mark this...